A Phase I Safety Study of NVG-291 in Healthy Adults - Trial NCT05308953
Access comprehensive clinical trial information for NCT05308953 through Pure Global AI's free database. This Phase 1 trial is sponsored by NervGen Pharma and is currently Recruiting. The study focuses on Spinal Cord Injury. Target enrollment is 72 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
NervGen Pharma
Timeline & Enrollment
Phase 1
May 06, 2021
Dec 01, 2022
Primary Outcome
Incidence of Adverse Events
Summary
This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded),
 placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to
 evaluate the safety and tolerability of NVG-291 administered by subcutaneous injection daily
 in healthy female participants. The trial is split into two parts, starting with Part 1 (SAD)
 and then Part 2 (MAD). In Part 1 (SAD), participants receive 1 dose on 1 day only and in Part
 2 (MAD), participants receive 1 dose every day for 14 days.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05308953
Non-Device Trial